非常低剂量的Everolimus治疗减少了结核性硬化综合疾病中的心脏瘤
Stefan Rupp1, Christian Jux1, David Backhoff1
1Pediatric Heart Center, Department of Pediatric Cardiology, Intensive Care Medicine and Congenital Heart Disease, Justus-Liebig University, Giessen, Germany.
Cardiology in the young
|August 20, 2025
概括
结核性硬化综合体 (TSC) 可能导致心脏瘤. 这项病例研究表明,即使在低血 (2-3 ng/ ml) 中,Everolimus疗法也有效地减少了TSC中的瘤大小.
科学领域:
- 心脏病学
- 癌症学
- 遗传学
背景情况:
- 结核性硬化综合体 (TSC) 是一种影响多个器官的遗传性疾病.
- 心脏肌瘤是TSC的常见表现,可能导致严重的血流阻塞.
- 目前对TSC相关心脏瘤的治疗选择有限.
研究的目的:
- 在结核性硬化综合症中报告成功使用Everolimus治疗心脏肌肉瘤的病例.
- 为了突出Everolimus的有效性,即使在以前未经记录的低血水平.
- 在TSC中建立间歇性Everolimus治疗的概念证明.
主要方法:
- 一名患有结核性硬化综合体和症状性心脏肌肉瘤的患者接受了Everolimus治疗.
- 根据临床反应和血液水平调整Everolimus的剂量.
- 由于临床决定,治疗需要重复停止和重新启动Everolimus.
主要成果:
- 观察到心脏肌瘤的显著回归.
- 在记录的低Everolimus血液水平为2-3 ng/ ml时发生瘤回归.
- 间歇性使用Everolimus证明了治疗效果.
结论:
- 在治疗结核性硬化综合症相关的心脏肌瘤方面,Everolimus是有效的.
- 在非常低的Everolimus血度下可以获得治疗效果.
- 按需或间歇的Everolimus治疗是治疗TSC的一种可行的策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
224
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
224


